Tumor-shed antigen CA125 blocks complement-mediated killing via suppression of C1q-antibody binding.

Tumor-shed antigen CA125 blocks complement-mediated killing via suppression of C1q-antibody binding.

C1q-engagement with IgG and IgM sort antibodies is the initiating step of classical complement-mediated immunity. The tumor shed antigen CA125 has been reported to have immunosuppressive results on host tumor responses in addition to commercially authorized and experimental monoclonal antibody … Read More

ImmPort: disseminating data to the public for the future of immunology.

ImmPort: disseminating data to the public for the future of immunology.

The immunology informationbase and evaluation portal (ImmPort) system is the archival repository and dissemination car for scientific and molecular informationunits created by analysis consortia funded by the Nationwide Institute of Allergy and Infectious Illnesses Division of Allergy, Immunology, and Transplantation. With almost 100 informationunits now … Read More